Immunosupportive therapies in aging

Tamas Fülöp1, Anis Larbi2, Katsuiku Hirokawa3, Eugenio Mocchegiani4, Bruno Lesourd5, Stephen Castle6, Anders Wikby7, Claudio Franceschi8, Graham Pawelec21Research Center on Aging, Immunology Program, Geriatric Division, Faculty of Medicine, University of Sherbrooke, Quebec, Canada;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tamas Fülöp, Anis Larbi, Katsuiku Hirokawa, Eugenio Mocchegiani, Bruno Lesourd, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/f8b18f654b774b01b9c5af9d1fcfa264
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8b18f654b774b01b9c5af9d1fcfa264
record_format	dspace
spelling	oai:doaj.org-article:f8b18f654b774b01b9c5af9d1fcfa2642021-12-02T02:51:08ZImmunosupportive therapies in aging1178-1998https://doaj.org/article/f8b18f654b774b01b9c5af9d1fcfa2642007-04-01T00:00:00Zhttps://www.dovepress.com/immunosupportive-therapies-in-aging-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Tamas Fülöp1, Anis Larbi2, Katsuiku Hirokawa3, Eugenio Mocchegiani4, Bruno Lesourd5, Stephen Castle6, Anders Wikby7, Claudio Franceschi8, Graham Pawelec21Research Center on Aging, Immunology Program, Geriatric Division, Faculty of Medicine, University of Sherbrooke, Quebec, Canada; 2Tübingen Ageing and Tumour Immunology Group, Center for Medical Research, University of Tübingen Medical School, Tübingen, Germany; 3Department of Pathology and Immunology Ageing and Developmental Sciences, Tokyo-Medical and Dental University Graduate School, Tokyo, Japan; 4Immunology Center, Section Nutrition, Immunity and Ageing, Research Department, Italian National Research Centres on Ageing, INRCA, Ancona, Italy; 5Hopital Universitaire de Clermont-Ferrand, Service Soins de Suite, Route de Châteaugay BP56, F-63118 Cebazat, France; 6Geriatric Research, Education and Clinical Center (GRECC), VA Greater Los Angeles Healthcare System and Multicampus Division of Geriatric and Gerontology, Department of Medicine, UCLA, Los Angeles, CA 90073, USA; 7School of Health Sciences, Jönköping University, Department of Natural Science and Biomedicine, Jönköping, Sweden; 8Italian National Research Center on Aging, Department of Experimental pathology, University of Bologna, Bologna, ItalyAbstract: The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.Keywords: immunosenescence, T cells, phagocytic cells, nutrition, vaccination, exercise, CMV, inflammaging, IRP, immunorestorative therapiesTamas FülöpAnis LarbiKatsuiku HirokawaEugenio MocchegianiBruno Lesourdet alDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 33-54 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Tamas Fülöp Anis Larbi Katsuiku Hirokawa Eugenio Mocchegiani Bruno Lesourd et al Immunosupportive therapies in aging
description	Tamas Fülöp1, Anis Larbi2, Katsuiku Hirokawa3, Eugenio Mocchegiani4, Bruno Lesourd5, Stephen Castle6, Anders Wikby7, Claudio Franceschi8, Graham Pawelec21Research Center on Aging, Immunology Program, Geriatric Division, Faculty of Medicine, University of Sherbrooke, Quebec, Canada; 2Tübingen Ageing and Tumour Immunology Group, Center for Medical Research, University of Tübingen Medical School, Tübingen, Germany; 3Department of Pathology and Immunology Ageing and Developmental Sciences, Tokyo-Medical and Dental University Graduate School, Tokyo, Japan; 4Immunology Center, Section Nutrition, Immunity and Ageing, Research Department, Italian National Research Centres on Ageing, INRCA, Ancona, Italy; 5Hopital Universitaire de Clermont-Ferrand, Service Soins de Suite, Route de Châteaugay BP56, F-63118 Cebazat, France; 6Geriatric Research, Education and Clinical Center (GRECC), VA Greater Los Angeles Healthcare System and Multicampus Division of Geriatric and Gerontology, Department of Medicine, UCLA, Los Angeles, CA 90073, USA; 7School of Health Sciences, Jönköping University, Department of Natural Science and Biomedicine, Jönköping, Sweden; 8Italian National Research Center on Aging, Department of Experimental pathology, University of Bologna, Bologna, ItalyAbstract: The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.Keywords: immunosenescence, T cells, phagocytic cells, nutrition, vaccination, exercise, CMV, inflammaging, IRP, immunorestorative therapies
format	article
author	Tamas Fülöp Anis Larbi Katsuiku Hirokawa Eugenio Mocchegiani Bruno Lesourd et al
author_facet	Tamas Fülöp Anis Larbi Katsuiku Hirokawa Eugenio Mocchegiani Bruno Lesourd et al
author_sort	Tamas Fülöp
title	Immunosupportive therapies in aging
title_short	Immunosupportive therapies in aging
title_full	Immunosupportive therapies in aging
title_fullStr	Immunosupportive therapies in aging
title_full_unstemmed	Immunosupportive therapies in aging
title_sort	immunosupportive therapies in aging
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/f8b18f654b774b01b9c5af9d1fcfa264
work_keys_str_mv	AT tamasfuumlloumlp immunosupportivetherapiesinaging AT anislarbi immunosupportivetherapiesinaging AT katsuikuhirokawa immunosupportivetherapiesinaging AT eugeniomocchegiani immunosupportivetherapiesinaging AT brunolesourd immunosupportivetherapiesinaging AT etal immunosupportivetherapiesinaging
_version_	1718402139391262720

Immunosupportive therapies in aging

Ejemplares similares